FUTURE PLANS

For further details of our future plans, please see the section headed "Business – Our Strategies" in this document.

[REDACTED]

We estimate that we will receive **[REDACTED]** of approximately HK$**[REDACTED]** after deducting the **[REDACTED]** payable by us in the **[REDACTED]**, assuming no **[REDACTED]** is exercised and assuming an **[REDACTED]** of HK$**[REDACTED]** per **[REDACTED]**, being the mid-point of the indicative **[REDACTED]** range of HK$**[REDACTED]** to HK$**[REDACTED]** per **[REDACTED]** in this document. If the **[REDACTED]** is set at HK$**[REDACTED]** per **[REDACTED]**, being the high end of the indicative **[REDACTED]** range, the **[REDACTED]** from the **[REDACTED]** will increase by approximately HK$**[REDACTED]**. If the **[REDACTED]** is set at HK$**[REDACTED]** per **[REDACTED]**, being the low end of the indicative **[REDACTED]** range, the **[REDACTED]** from the **[REDACTED]** will decrease by approximately HK**[REDACTED]**.

We intend to use the **[REDACTED]** we will receive from this **[REDACTED]** for the following purposes:

I. Further Development and Commercialisation of our MB2 Inkjet Printers

- approximately **[REDACTED]**% of the **[REDACTED]**, or HK$**[REDACTED]**, will be used for the further development and commercialisation of our MB2 Inkjet Printers, which is designed to support the transition of the product from the prototype stage to commercial production and market deployment ("**[REDACTED] for MB2 Inkjet Printers**"). The **[REDACTED]** will be applied to establishing production capability, completing product testing and certification, securing key production materials and supporting the mass production in the future. We expect to utilise such **[REDACTED]** within approximately 24 months following the **[REDACTED]**.

  (i) approximately **[REDACTED]**% of the **[REDACTED]** for MB2 Inkjet Printers, or HK$**[REDACTED]**, will be used for manufacturing system establishment and pilot production preparation, which is expected to be utilised within the first 6 months following the **[REDACTED]**. Having completed the prototype development stage, we plan to allocate these funds towards establishing the production infrastructure required for commercial manufacturing of the MB2 Inkjet printer. In particular:

    - approximately HK$**[REDACTED]** will be used for the development, procurement and modification of injection moulds, metal stamping moulds and other tooling required for the production of newly designed structural components;

    - approximately HK$**[REDACTED]** will be used for pilot production activities, including procurement of raw materials and components, outsourced processing services, assembly testing and production verification for an initial production batch; and

    - approximately HK$**[REDACTED]** will be used for the acquisition and installation of dedicated production fixtures, testing equipment and production-line adaptation facilities required for inkjet printing technology, which are separate from and not compatible with our existing dot-matrix printer manufacturing lines.

(ii) approximately **[REDACTED]**% of the **[REDACTED]** for MB2 Inkjet Printers, or HK$**[REDACTED]**, will be used for product testing, certification and intellectual property protection, which is expected to be utilised within the first 6 months following the **[REDACTED]**. The **[REDACTED]** will be primarily allocated to complete the final stage of product commercialisation and regulatory compliance, including: (1) engaging independent third-party laboratories to conduct reliability, durability and environmental testing, including high-temperature, low-temperature, humidity, vibration and long-duration operational testing; (2) obtaining product certifications and regulatory approvals required for commercial sales in our target markets, including CE, RoHS and other applicable safety and environmental certifications; (3) conducting software compatibility testing and optimisation of printer drivers and application software; and (4) filing patents and implementing intellectual property protection measures relating to the MB2 Inkjet project.

(iii) approximately **[REDACTED]**% of the **[REDACTED]** for MB2 Inkjet Printers, or HK$**[REDACTED]**, will be used to establish and support our engineering and technical personnel team, which is expected to be utilised within 18 months following the **[REDACTED]**. The **[REDACTED]** will primarily be used to cover staff costs for recruiting and retaining engineering and technical personnel, including project management, mechanical engineering, electrical engineering, software engineering, testing and on-site technical support functions. Through strengthening our technical workforce, we aim to enhance our product development capabilities, improve project execution efficiency and support the implementation of our business development strategies.

(iv) approximately **[REDACTED]**% of the **[REDACTED]** for MB2 Inkjet Printers, or HK$**[REDACTED]**, will be used for the implementation and delivery support of our MB2 Inject printer products, which is expected to be utilised between 6 and 24 months following the **[REDACTED]**. The **[REDACTED]** will primarily be applied towards supporting the deployment of the MB2 Inkjet project for our future customers, including: (1) on-site installation, commissioning and technical support services provided by our engineering personnel; (2) localisation, translation and preparation of technical documentation, operation manuals and training materials; and (3) procurement of spare parts, consumables and support materials required during the initial deployment.

A summary of the above-mentioned implementation plan is as follows:

Period	Manufacturing system establishment and pilot production preparation	Product testing, certification and intellectual property protection	Establishment of our engineering and technical personnel team	The implementation and delivery support of our MB2 Inject printer products

[REDACTED]

II. Commercialisation of EMR Module

- approximately **[REDACTED]**% of the **[REDACTED]**, or HK$**[REDACTED]**, will be used for the research and development, industrialisation and commercialisation of the our EMR Module ("**[REDACTED] for EMR Module**"). The project aims to strengthen our technological capabilities through the development of proprietary EMR-related core technologies and self-developed driver chips, establish in-house manufacturing capabilities for EMR modules, enhance supply chain control and support the commercialisation of EMR solutions for banking, financial and other digital handwriting application scenarios. We expect to utilise the relevant **[REDACTED]** within approximately 24 months following the **[REDACTED]**.

  (i) *First Phase – Technology Development and Manufacturing Capability Establishment.* Approximately **[REDACTED]**% of the **[REDACTED]** for EMR Module, or HK$**[REDACTED]**, will be utilised within the first 24 months following the **[REDACTED]**.

    - Approximately HK$**[REDACTED]**, will be used for the development and industrialisation of our proprietary EMR driver chips and the procurement of critical electronic components. The **[REDACTED]** will be used for chip architecture optimisation, integrated circuit design, intellectual property licensing, tape-out, wafer fabrication, packaging and testing, engineering verification and pilot production of stylus-end and display-end driver chips. A portion of the **[REDACTED]** will also be used for the procurement of key sensors and other core components required for initial production planning. Upon completion, we expect to establish proprietary chip technologies for EMR modules and reduce our reliance on third-party chip suppliers.

    - Approximately HK$**[REDACTED]**, will be used to establish dedicated EMR module manufacturing capabilities. The **[REDACTED]** will be used for the procurement, installation and commissioning of production and testing equipment, including high-precision bonding machines, automated calibration systems, EMC testing systems and related manufacturing equipment. The **[REDACTED]** will also be used for production-line engineering works and clean- room upgrades required for EMR module manufacturing. Upon completion, we expect to develop in-house production capabilities covering key manufacturing processes of EMR modules.

    - Approximately HK$**[REDACTED]**, will be used for product certification, testing and regulatory compliance activities. The **[REDACTED]** will be used to obtain certifications and testing reports required for commercialisation, including electromagnetic compatibility, electrical safety and other applicable regulatory requirements in our target markets. Upon completion, we expect to obtain the certifications necessary for commercial deployment of EMR modules.

  (ii) *Second Phase – Product Development and Commercialisation.* Approximately **[REDACTED]**% of the **[REDACTED]** for EMR Module, or HK$**[REDACTED]**, will be utilised to support the research and development team dedicated to the EMR Module project within the first 18 months following the **[REDACTED]**. The **[REDACTED]** will primarily be used for personnel expenses relating to chip development, manufacturing process optimisation, software and firmware enhancement, testing and reliability verification activities. The **[REDACTED]** will also support continuous product improvement and technical upgrades based on customer requirements and application scenarios. Upon completion, we expect to further enhance product performance, improve manufacturing yields and strengthen the technical capabilities of our EMR Module platform.

A summary of the above-mentioned implementation plan is as follows:

	First Phase			Second Phase
Period	**EMR Driver Chip Development and Critical Component Procurement**	**EMR Module Manufacturing Capability Development**	**Product Certification, Testing and Regulatory Compliance**	**EMR Module R&D Team and Continuous Product Development**

[REDACTED]

III. Working Capital and Other General Corporate Purposes

- The remaining **[REDACTED]**% of the **[REDACTED]**, or HK$**[REDACTED]**, will be used for working capital and other general corporate purposes.

The above allocation of the **[REDACTED]** from the **[REDACTED]** will be adjusted on a pro rata basis in the event that the **[REDACTED]** is fixed at a higher or lower level compared to the mid-point of the indicative **[REDACTED]** range stated in this Document.

If the **[REDACTED]** is exercised in full, and **[REDACTED]** that we will receive will be approximately HK$**[REDACTED]**, assuming an **[REDACTED]** of HK$**[REDACTED]** per Share (after deducting the estimated **[REDACTED]** payable by us in connection with the **[REDACTED]**, being the mid- point of the indicative **[REDACTED]** range). In the event that the **[REDACTED]** is exercised in full, we intend to apply the additional **[REDACTED]** to the above purpose in the proportions stated above.

To the extent that the **[REDACTED]** from the **[REDACTED]** are not immediately used for the purposes described above and to the extent permitted by the relevant laws and regulations, they will be placed in short-term demand deposits with authorised and licensed commercial banks or financial institutions.

We will issue an appropriate announcement if there is any material change to the above proposed use of **[REDACTED]**.